002262 恩华药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入4,470,9897.85%5,697,6335,041,5044,298,5133,935,664
减:营业总成本3,262,9958.92%4,403,8723,912,0193,358,8173,035,596
    其中:营业成本1,072,024-1.47%1,506,5411,369,8431,020,461897,330
               财务费用(14,736)21.12%(17,127)(19,261)(20,784)(10,449)
               资产减值损失(8,321)-32.47%(39,070)(33,269)(16,189)(35,346)
公允价值变动收益------------
投资收益47,0108.38%65,56951,04436,27336,226
    其中:对联营企业和合营企业的投资收益8,92030.24%20,2899,6404,5871,326
营业利润1,245,3056.31%1,336,5741,182,3441,003,465925,866
利润总额1,233,5577.04%1,296,6881,168,644989,907915,776
减:所得税费用129,031-5.03%155,896134,397109,819117,754
净利润1,104,5268.66%1,140,7921,034,247880,088798,021
减:非控股权益(1,522)-57.38%(2,772)(2,671)(20,622)244
股东净利润1,106,0478.42%1,143,5641,036,918900,709797,777

市场价值指针
每股收益 (元) *1.0907.92%1.1301.0300.8900.790
每股派息 (元) *----0.3600.3200.2000.200
每股净资产 (元) *7.97813.67%7.1846.3865.5804.884
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容